WO1989004311A1 - Polycyclicamines with psychotropic activity - Google Patents

Polycyclicamines with psychotropic activity Download PDF

Info

Publication number
WO1989004311A1
WO1989004311A1 PCT/US1988/003924 US8803924W WO8904311A1 WO 1989004311 A1 WO1989004311 A1 WO 1989004311A1 US 8803924 W US8803924 W US 8803924W WO 8904311 A1 WO8904311 A1 WO 8904311A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
name
etheno
pyridinyl
cyclobut
Prior art date
Application number
PCT/US1988/003924
Other languages
French (fr)
Inventor
Magid A. Abou-Gharbia
Usha R. Patel
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of WO1989004311A1 publication Critical patent/WO1989004311A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Definitions

  • This invention relates to novel compounds having utility in the treatment of central nervous systems disorders such as anxiety, psychosis, depression and sexual dysfunction.
  • Recent research has provided a growing body of literature which attributes the activity of some of the newer classes of CNS agents to their selective activation of the serotonin receptor subtype designated the 5-HTIA receptor.
  • buspirone (8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ] butyl ]-8-azaspiro[4.5 ]decane-7,9-dione
  • TVX Q 7821 (2-[4-[4-(2-pyrimidinylM-piperazinyl ] butyl ]-l,2-benziso- thiazol-3-(2H)one 1,1-dioxide hydrochloride).
  • buspirone-like compounds activating the 5-HTIA receptor site are useful as anxiolytics/antipsyehoties, antidepressants and in the treatment of sexual dysfunction.
  • the compounds of the invention are characterized by the formula
  • X is lower alkylene, vinylene or O
  • Y is lower alkylene or vinylene; n is 2 - 4; the dotted line represents an optional double bond; m is 1 - 3; A is phenyl, benzoyl, pyridinyl, quinolinyl or quinoxalinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo, cyano, nitro or trifluoromethyl; or when m is >1, A represents the grouping
  • B is phenyl, pyrimidinyl, pyridinyl or pyrazinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo f cyano, nitro or trifluoromethyl, with the proviso that where R
  • A is other than unsubstituted or substituted benzoyl or pyridinyl; and the pharmacologically acceptable salts thereof.
  • lower alkyl refers to moieties having 1 - 6 carbon atoms in the carbon chain.
  • lower alkylene refers to moieties having 1 - 4 carbon atoms in the carbon chain.
  • lower alkoxy refers to moieties having 1 - 6 carbon atoms.
  • halo refers to fluoro, chloro and bromo.
  • the compounds of the invention can form pharmacologically acceptable salts from pharmacologically acceptable organic and inorganic acids such as hydrochloric, hydrobromic, sulfonie, sulfuric, phosphoric, nitric, maleic, fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, mandelic, cinnamic, palmitic, itaconic and benzenesulfonic.
  • pharmacologically acceptable organic and inorganic acids such as hydrochloric, hydrobromic, sulfonie, sulfuric, phosphoric, nitric, maleic, fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, mandelic, cinnamic, palmitic, ita
  • This intermediate product can then be reacted with, for example, an appropriately substituted 4-piperazinylalkylhalide to yield the desired final product: - 4 -
  • polycyclie amine intermediate can be reacted with a suitable dihalo lower alkane, followed by reaction with a suitable A-substi- tuent starting material:
  • B, A and m are as defined hereinbefore and hal is a halo atom, such as chloro or bromo.
  • hal is a halo atom, such as chloro or bromo.
  • compounds of the invention or the pharmacologically acceptable salts thereof can be prepared by subjecting a cyclic amine having the formula
  • maleimide can first be reacted with a dihalo lower alkane followed by reaction with an appropriate A substituent-containing starting material to yield the following intermediate:
  • the saturated analogs of the compounds discussed in all of the previous preparative schemes can be prepared by hydrogenating the intermediates or the final products using hydrogen and Pd/C as a catalyst.
  • the compounds of the invention may exist either in the form of the free base or the pharmacologically acceptable salts. Methods for converting one such form to another will be obvious to one skilled in the chemical arts.
  • the compounds of the invention display a pharmacological profile like that of the compound buspirone (8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ]- butyl ]-8-azaspiro[4.5 ]decane-7,9-dione).
  • buspirone 8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ]- butyl ]-8-azaspiro[4.5 ]decane-7,9-dione.
  • the latter compound has demonstrated preclinical activity in antipsychotic paradigms and has also displayed a unique clinical anxioselective profile, whereby its efficacy in the treatment of anxiety neuroses is comparable to the benzodiazepine diazepam but without the benzodiazepine-related side effects.
  • the clinically effective anxiolytic doses of the benzodiazepines produce such undesirable side effects as ataxia, muscle relaxation and sedation.
  • the compounds of the invention in a manner similar to buspirone, display preelinical antipsychotic activity with minimal or no side effects. Moreover, based on their buspirone- like profile, the compounds of the invention can be considered of clinical value in treating anxiety neuroses, depression as well as sexual dysfunction.
  • the effective dosage of the substances active for such treatment will vary according to the particular compound being employed, the severity and nature of condition being treated. Therapy should be initiated at lower doses (in mg/kg/day), the dosage thereafter being increased, if necessary, to produce the desired effect.
  • the compounds of the invention are most desirably administered at a concentration that will generally afford effective results without causing any harmful or deleterious effects.
  • the compounds of the invention can be formulated into oral dosage forms such as tablets, capsules and the like.
  • the compounds can be administered alone- or by combining them with conventional carriers, such as magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium car boxy methyleellulose, low melting wax, cocoa butter and the like. Diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, tablet-disintegrating agents and the like may be employed.
  • the compounds may be encapsulated with or without other carriers. In all cases, the proportion of active ingrdients in said compositions both solid and liquid will be at least to impart the desired activity thereto on oral administration.
  • the compounds may also be injected parenterally in which case they are used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
  • a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
  • the activity profile of the compounds of the invention and their substantial lack of extrapyramidal side effects may be demonstrated by standard pharmacological procedures, which are described more fully in the examples given hereafter.
  • Example 1 shows the preparation and pharmacological testing of compounds within the invention.
  • the methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
  • the title compound is separated by preparative HPLC using methanol as the eluent and is converted to the dihydrochloride salt, m.p. 173-174°C (2 g, 51% yield).
  • the methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
  • the title compound is separated by preparative HPLC using methanol as the an eluent and is converted to the dihydrochloride salt, m.p. 149-150°C (2.5 g, 54.4% yield).
  • reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride.
  • the methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
  • the ex vivo inhibition of 5-HT ⁇ serotonin receptor binding assay is used to determine whether the test compounds can cross the blood-brain barrier and affect the receptor in question and to give an indication of buspirone-like activity.
  • the assay is carried out as follows:
  • rats Several groups of rats (4 - 6 rats/group) are injected with test compound or the appropriate vehicle. Thirty minutes later, unless otherwise noted, rats are decapitated and their brains removed. Various brain regions are dissected and rapidly frozen and maintained at -70° C until used.
  • the homogenate is then centrifuged at 20,000 rpm (RC5-B; 40,000 g) and the supernatant discarded.
  • the pellet is resuspended in 40 vols of the same buffer and incubated at 37° C for 10 minutes to aid in the removal of endogenous seroton
  • the homogenate (50 ⁇ l; 0.4-0.6 mg protein/sample) is incubated with 100 ⁇ l (1.5-1.8 nM) 3 H-8-hydroxy-2-(di-n-propylamino)tetraline in a final volume of 2 ml of buffer for 10 minutes at 37° C.
  • 3 ml of cold buffer A are added to each tube, and the contents rapidly filtered through Whatman GF/B glass filters.
  • the filters are then rapidly washed 2 times with 3 ml of the same buffer, placed in scintillation vials, and shaken for 15 minutes with 10 ml of Hydrofluor (National Diagnostics) scintillation cocktail.
  • the vials are then counted in a Packard 460 CD scintillation counter.
  • Specific binding is calculated for each of the treatment protocols and is defined as total binding less binding in the presence of excess unlabeled serotonin (1 ⁇ M). Specific binding obtained in vehicle-treated rats is compared to that obtained in animals receiving a single or various doses of test compound and expressed as percent of control. These results are then plotted as logit % binding vs. log concentration of test drug. Linear regression analysis then yields a straight line with 95% confidence limits from which an IC5Q can be inversely predicted. K[ (inhibition constant) for the test drug is then calculated by the formula:
  • test compound also permits the calculation of an ID50 value, i.e. an inhibitory dose that displaces 50% of the specific binding ex vivo.
  • ID50 value i.e. an inhibitory dose that displaces 50% of the specific binding ex vivo.
  • buspirone (30 mg/kg) displaced 46% of specific 3H-8-OH-DPAT binding from hippocampal membranes.
  • the compounds of the invention gave the following results.
  • the compounds of the invention are also studied for their ability to inhibit limbic D-2 dopamine receptor binding.
  • This in vitro assay measures the ability of the compounds tested to bind to the dopamine receptor sites. Those compounds which exhibit a weak binding effect have a low liability to display potential extrapyramidal side effects.
  • Limbic brain tissue (nucleus accumbens, septal area, olfactory tubercle) is dissected and homogenized on ice in 9 volumes of buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM C1, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.1% L-ascorbic acid, 10 ⁇ M pargyline HC1, pH 7.1) using a Polytron homogenizer at setting 5 for three 15-sec bursts. The homogenate is then diluted 4-fold with buffer and centrifuged at 30,000 x g for 20 minutes, and the supernatant is discarded.
  • buffer 50 mM Tris-HCl, 120 mM NaCl, 5 mM C1, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.1% L-ascorbic acid, 10 ⁇ M pargyline HC1, pH 7.1
  • the pellet is resuspended in the same volume of buffer and recentrifuged as before, again discarding the supernatant. This pellet is then resuspended in the same volume of buffer used in the homogenization, and the protein content of this preparation is assayed by the Lowry method.
  • the homogenate is stored frozen at -70° C until use.
  • the filters are then rapidly washed 3 times with 3 ml of the same buffer, placed in scintillation vials, and shaken for 15 minutes with 10 ml of Hydrofluor (National Diagnostics) scintillation cocktail.
  • the vials are then counted in a Packard 460 CD scintillation counter.
  • Specific binding is defined as total binding less binding in the presence of 1 ⁇ M (+)butaclamol. Binding in the presence of various concentra- tions of test drug is expressed as a percent of specific binding when no drug is present. These results are then plotted as logit % binding vs. log concentra ⁇ tion of test drug. " Linear regression analysis then yields a straight line with 95% confidence limits from which an IC50 can be inversely predicted. Kj (inhibition constant) for the test drug is then calculated by the formula:

Abstract

There are disclosed compounds of formula (I), wherein R represents (II), (III) or (IV), where X is lower alkylene, vinylene or O; Y is lower alkylene or vinylene; n is 2 - 4; the dotted line represents an optional double bond; m is 1 - 3; A is phenyl, benzoyl, pyridinyl, quinolinyl or quinoxalinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo, cyano, nitro or trifluoromethyl; or when m is > 1, A represents the grouping (V), where B is phenyl, pyrimidinyl, pyridinyl or pyrazinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo, cyano, nitro or trifluoromethyl, with the proviso that where R is (II), A is other than unsubstituted or substituted benzoil or pyridinyl; and the pharmacologically acceptable salts thereof and their use as antipsychotic/anxiolytic and antidepressant agents and in the treatment of sexual dysfunction and having a low liability for extrapyramidal side effects.

Description

POLYCYCLICAMINES WITH PSYCHOTROPIC ACTIVITY
This invention relates to novel compounds having utility in the treatment of central nervous systems disorders such as anxiety, psychosis, depression and sexual dysfunction. Recent research has provided a growing body of literature which attributes the activity of some of the newer classes of CNS agents to their selective activation of the serotonin receptor subtype designated the 5-HTIA receptor. This has been the case especially for compounds such as buspirone (8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ] butyl ]-8-azaspiro[4.5 ]decane-7,9-dione) and TVX Q 7821 (2-[4-[4-(2-pyrimidinylM-piperazinyl ] butyl ]-l,2-benziso- thiazol-3-(2H)one 1,1-dioxide hydrochloride). See Eison et al., Pharmacol. Biochem. and Behav., 24, 701 (1986); Dompert et al., Naunyn-Schmiedeberg Arch. Pharmacol., 328, 467 (1985) and Spencer and Traber, Psychopharmacol., 91, 25 (1987). Both of the compounds cited above are anxiolytics which demonstrate binding at the 5-HTIA site, while other classic anxiolytics, such as the benzodiazepines and pentobarbital, do not act via the 5-HTIA receptor. Moreover, compounds such as TVX Q 7821 have been found to possess anti¬ depressant activity (see West German Patent Application No. 3,321, 969A) while buspirone has been found to be useful in the treatment of sexual dysfunction (see U.S. Patent No. 4,640,921).
Accordingly, buspirone-like compounds activating the 5-HTIA receptor site, such as those of the present invention, are useful as anxiolytics/antipsyehoties, antidepressants and in the treatment of sexual dysfunction. The compounds of the invention are characterized by the formula
Figure imgf000003_0001
wherein R represents
Figure imgf000003_0002
where X is lower alkylene, vinylene or O;
Y is lower alkylene or vinylene; n is 2 - 4; the dotted line represents an optional double bond; m is 1 - 3; A is phenyl, benzoyl, pyridinyl, quinolinyl or quinoxalinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo, cyano, nitro or trifluoromethyl; or when m is >1, A represents the grouping
Figure imgf000004_0001
where B is phenyl, pyrimidinyl, pyridinyl or pyrazinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halof cyano, nitro or trifluoromethyl, with the proviso that where R
Figure imgf000004_0002
A is other than unsubstituted or substituted benzoyl or pyridinyl; and the pharmacologically acceptable salts thereof.
The term "lower alkyl" refers to moieties having 1 - 6 carbon atoms in the carbon chain. The term "lower alkylene" refers to moieties having 1 - 4 carbon atoms in the carbon chain. The term "lower alkoxy" refers to moieties having 1 - 6 carbon atoms. The term "halo" refers to fluoro, chloro and bromo.
The compounds of the invention can form pharmacologically acceptable salts from pharmacologically acceptable organic and inorganic acids such as hydrochloric, hydrobromic, sulfonie, sulfuric, phosphoric, nitric, maleic, fumaric, benzoic, ascorbic, pamoic, succinic, methanesulfonic, acetic, propionic, tartaric, citric, lactic, malic, mandelic, cinnamic, palmitic, itaconic and benzenesulfonic.
The compounds of the invention may be prepared by a variety of synthetic routes using conventional methods. Thus, compounds in which R is
Figure imgf000005_0001
can be prepared, for example, by reacting maleimide with an appropriate diene, e.g. 1,3,5,7-cyclooctatetraene, to yield a precursor which when reduced with LiAlH4 in tetrahydrofuran yields a polycyclic amine intermediate:
Figure imgf000005_0002
Figure imgf000005_0003
This intermediate product can then be reacted with, for example, an appropriately substituted 4-piperazinylalkylhalide to yield the desired final product: - 4 -
Figure imgf000006_0001
Figure imgf000006_0002
In the alternative, the polycyclie amine intermediate can be reacted with a suitable dihalo lower alkane, followed by reaction with a suitable A-substi- tuent starting material:
Figure imgf000006_0003
Figure imgf000006_0004
In the above sequences, B, A and m are as defined hereinbefore and hal is a halo atom, such as chloro or bromo. Further, compounds of the invention or the pharmacologically acceptable salts thereof can be prepared by subjecting a cyclic amine having the formula
R NH
to alkylation to introduce a substituted alkyl group having the formula -(CH2)m~A; or a piperazine derivative having the formula
Figure imgf000007_0002
is subjected to alkylation to introduce a substituted alkyl group having the formula
R N-(CH2) -
or an imide having the formula
Figure imgf000007_0001
is reduced; wherein in the above preparative sequences R, A, B and m are as defined hereinbefore. The above reaction sequences can also be used to prepare compounds with other R moieties. Thus, by selecting a diene of appropriate ring size and degree of unsaturation, it is possible to prepare other polycyclie amine intermediates:
Figure imgf000008_0001
Figure imgf000008_0002
Figure imgf000008_0003
Figure imgf000008_0004
In yet another alternative preparative sequence, maleimide can first be reacted with a dihalo lower alkane followed by reaction with an appropriate A substituent-containing starting material to yield the following intermediate:
Figure imgf000009_0001
which can then be further subjected to Diels-Alder addition with appropriate reactants and after reduction yields desired final products.
The saturated analogs of the compounds discussed in all of the previous preparative schemes can be prepared by hydrogenating the intermediates or the final products using hydrogen and Pd/C as a catalyst.
Some of the starting polycyclie amine intermediates useful in preparing the compounds of the invention can be obtaine . commercially. Thus, the compound 3-azabicyclo[3.2.2 ]nonane is commercially available and can be used directly to prepare the desired final products. All other starting materials used in the above-described preparative routes are commercially available or can be made according to procedures taught in the chemical literature.
Of course, other methods of preparation, which will occur to those skilled in the art, may also be employed to prepare the compounds of the invention.
The compounds of the invention may exist either in the form of the free base or the pharmacologically acceptable salts. Methods for converting one such form to another will be obvious to one skilled in the chemical arts.
The compounds of the invention display a pharmacological profile like that of the compound buspirone (8-[4-[4-(2-pyrimidinyl)-l-piperazinyl ]- butyl ]-8-azaspiro[4.5 ]decane-7,9-dione). The latter compound has demonstrated preclinical activity in antipsychotic paradigms and has also displayed a unique clinical anxioselective profile, whereby its efficacy in the treatment of anxiety neuroses is comparable to the benzodiazepine diazepam but without the benzodiazepine-related side effects. The clinically effective anxiolytic doses of the benzodiazepines produce such undesirable side effects as ataxia, muscle relaxation and sedation. Additionally, most chronically used antipsychotic drugs, cause extrapyramidal side effects, such as pseudoparkin- sonism, tardive dyskinesia and the like. Ideally, treatment of psychoses and anxiety should be free of any undesirable side effects. The compounds of the invention, in a manner similar to buspirone, display preelinical antipsychotic activity with minimal or no side effects. Moreover, based on their buspirone- like profile, the compounds of the invention can be considered of clinical value in treating anxiety neuroses, depression as well as sexual dysfunction.
When employed as anxiolytics/antipsyehoties, antidepressants or in treating sexual dysfunction, the effective dosage of the substances active for such treatment will vary according to the particular compound being employed, the severity and nature of condition being treated. Therapy should be initiated at lower doses (in mg/kg/day), the dosage thereafter being increased, if necessary, to produce the desired effect. In general, the compounds of the invention are most desirably administered at a concentration that will generally afford effective results without causing any harmful or deleterious effects. When the compounds of the invention are employed as anxiolytics/- antipsychotic agents, antidepressants or in the treatment of sexual dysfunction, they can be formulated into oral dosage forms such as tablets, capsules and the like. The compounds can be administered alone- or by combining them with conventional carriers, such as magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium car boxy methyleellulose, low melting wax, cocoa butter and the like. Diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, tablet-disintegrating agents and the like may be employed. The compounds may be encapsulated with or without other carriers. In all cases, the proportion of active ingrdients in said compositions both solid and liquid will be at least to impart the desired activity thereto on oral administration. The compounds may also be injected parenterally in which case they are used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic. The activity profile of the compounds of the invention and their substantial lack of extrapyramidal side effects may be demonstrated by standard pharmacological procedures, which are described more fully in the examples given hereafter.
The following examples show the preparation and pharmacological testing of compounds within the invention. Example 1
2>3,3a,4,4a,6a,7,7a-Octahydro-2-[3-(3-pyridinyl)propyl 3-4,7- etheno-lH-eyclobut[f lisoindole, dihydrochloride, 3/4 hydrate
To a stirred solution of 2,3,3a,4,4a,6a,7,7a-octahydro-4,7-etheno- lH-cyclobut[f lisoindole (3 g; 0.017 mol), sodium carbonate (3.5 g, 0.035 mol) and triethylamine 3 mL in 50 mL of dimethylformamide is added 3-pyridinyl- propylbromide hydrobromide (4.7 g, 0.017 mol). The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound as free base is separated by preparative HPLC using methanol as the eluent (Rf = 0.25) and is converted to the hydrochloride salt; m.p. 195-197°C (2 g; 40% yield from ethanol-ether 1:1). Analysis for: C20H24N2 • 2 HC1 • 3/4 H2O Calculated: C, 60.52; H, 7.44; N, 7.06 Found: C, 60.42; H, 7.39; N, 6.91.
Example 2 l-(4-Fluorophenyl)-4-(l,3,3a,4,-a,6a,7,7a-oct-_ ydro-4,7-etheno-2H- cyclobutlf ]isoindol-2-yl)-l-butanone, hydrochloride, 3/4 hydrate
To a stirred solution of 2,3,3a,4,4a,6a,7,7a-octahydro-4,7-etheno- lH-cyclobut[f lisoindole (3 g; 0.017 mol), sodium carbonate (3.5 g, 0.035 mol), and triethylamine 3 mL in 50 mL of dimethylformamide is added 4-chloro-4'- fluorobutyrophenone (3.5 g; 0.017 mol). The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the hydrochloride salt; m.p. 209- 210°C (2.5 g; 43% yield). Analysis for: C22H24NOF • HC1 • 3/4 H2O Calculated: C, 68.21; H, 6.84; N, 3.61 Found: C, 68.02; H, 6.49; N, 3.53 Example 3 l-(4-Fluorophenyl)-4r(3,3a,4,5,6,7,8,8a-octehyd_,o-4,8-ethenocyclo- hepta[e]pyrrol-2(lH>-yl)-l-butanone, hydrochloride, hydrate
To a stirred solution of 3,3a,4,5,6,7,8,8a-octahydro-4,8-etheno- cyclohepta[cl yrrole (3.2 g, 0.019 mol), sodium carbonate (3.5 g, 0.035 mol) and triethylamine 3 mL in 50 mL of dimethylformamide is added 4-chloro-4'- fluorobutyrophenone (3.94 g, 0.019 mol). The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the hydrochloride salt; m.p. 177- 179° C (1.5 g, 24% yield). Analysis for: C2ιH26 OF • HC1 • H2O Calculated: C, 66.05; H, 7.60; N, 3.67 Found: C, 65.85; H, 7.0; N, 3.77.
Example 4 2,3,3a,4,4a,5,6,6a,7,7a-De<Mhydro-2-^2- 2- ιuinθ-inyl)ethyl 3-4,7- etheno-2H-eyclobut[f lisoindole, dihydrochloride, hydrate
A mixture of 2,3,3a,4,4a,5,6,6a,7,7a-decahydro-4,7-etheno-2H- eyclobut[f lisoindole (5.0 g, 0.028 mol), 2-vinylquinoline (7.75 g, 0.5 mol) and 2 mL of glacial acetic acid is refluxed for 48 hours in 150 mL of methanol. The solvent is removed under vacuum and the residue is dissolved in methylene chloride. The methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the dihydrochloride salt; m.p. 128-130°C (5 g, 54% yield). Analysis for: C23H26N2 • 2 HC1 • H2O
- Calculated: C, 65.55; H, 7.12; N, 6.65
Found: C, 65.57; H, 7.4; N, 6.17. Example 5
2,3,3a,4,4a,6a,7,7a-Oct^ydro-2-[2-(2-pyridinyl)ethyll-4,7-etheno- lH-cyclobut[f lisoindole, dihydroehloride, hemihydrate
A mixture of 2,3,3a,4,4a,6a,7,7a-octahydro-4,7-etheno-lH-cyclo- but[f lisoindole (2.5 g, 0.014 mol), 2-vinylpyridine (3 g, 0.03 mol) and 2 mL of glacial acetic acid is refluxed for 48 hours in 150 mL of methanol. The solvent is removed under vacuum and the residue is dissolved in methylene chloride.
The methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the dihydrochloride salt, m.p. 173-174°C (2 g, 51% yield).
Analysis for: C19H22 2 * HC1 • 1/2 H2O
Calculated: C, 63.77; H, 7.41; N, 7.83 Found: C, 63.83; H, 7.82; N, 7.72.
Example 6
2,3,3a,4,4a,5,6,6a,7,7a-Decahydro"2-[2-(2-pyridinyl)ethyl 3-4,7- etheno-lH-cyclobut[f lisoindole, dihydroehloride, 1/4 hydrate
A mixture of 2,3,3a,4,4a,5,6,6a,7,7a-decahydro-4,7-etheno-lH- cyclobut[f lisoindole (5 g, 0.028 mol), 2-vinylpyridine (5.25 g, 0.05 mol) and 2 mL of glacial acetic acid is refluxed for 48 hours in 150 mL of methanol. The solvent is removed under vacuum and the residue is dissolved in methylene chloride. The methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the dihydrochloride salt, m.p. 173-174°C (5 g, 63.7% yield). Analysis for: C19H24N2 • 2 HC1 • 1/4 H20 Calculated: C, 63.77; H, 7.41; N, 7.83 Found: C, 63.83; H, 7.82; N, 7.72. Example 7
2,3,3a,4,_a,6a,6,7,7a-Octahydro-2-[2-(2- ju_nolinyl)ethyl3-4,7-etheno- lH-cyclobut[f lisoindole, dihydrochloride, 1 1/4 hydrate
A mixture of 2,3,3a,4,4a,6a,7,7a-octahydro-4,7-etheno-lH-eyelo- but[f lisoindole (2.59 g, 0.014 mol), 2-vinylquinoline (4.5 g, 0.03 mol) and 2 mL glacial acetic acid is refluxed for 48 hours in 150 mL of methanol. The solvent is removed under vacuum and the residue is dissolved in methylene chloride.
The methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The title compound is separated by preparative HPLC using methanol as the an eluent and is converted to the dihydrochloride salt, m.p. 149-150°C (2.5 g, 54.4% yield).
Analysis for: C23H24N2 • 2 HC1 • 1 1/4 H2O
Calculated: C, 65.17; H, 6.72; N, 6.61 Found: C, 65.08; H, 6.54; N, 6.38.
Example 8
3-[3-[4-(3-ChlorophenyI>-l-piperazinyl 3 propyl 3-3- azabieyclo[3.2.2 lnonane, dihydrochloride
To a stirred solution of 3-azabieyclo[3.2.2 Inonane (4 g, 0.032 mol), sodium carbonate (4 g, 0.045 mol) and triethylamine 3 mL in 50 mL of dimethylformamide is added 4-(3-chlorophenyl -l-piperazinylpropylchloride hydrochloride (4 g, 0.0115 mol). The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the hydrochloride salt; m.p. >280°C (1 g; 24.5% yield). Analysis for: C21H32N3CI • 2 HC1
Calculated: C, 58.0; H, 7.82; N, 9.67 Found: C, 57.81; H, 7.77; N, 9.46. Example 9
2-[3-[4-(3-Chlorophenyl)-l-piperaziιιyl 3propyl 3-2,3,3a,4,4a,5,6,7,7a-deca- hydro-4,7-etheno-lH-cyclobut[f lisoindole, trihydrochloride, dihydrate
To a stirred solution of 2,3,3a,4,4a,5,6,6a,7,7a-decahydro-4,7- etheno-lH-cyclobut[f lisoindole (2 g, 0.0115 mol), sodium carbonate (4.6 g,
0.046 mol) and triethylamine 3 mL in 50 mL of dimethylformamide is added 4-
(3-chlorophenyl)-l-piperazinylpropylchloride hydrochloride (4 g, 0.0115 mol).
The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the hydrochloride salt; m.p. 270-
272°C (1 g, 21% yield). Analysis for: C25H34N4CI • 2 HC1 • 2 H2O
Calculated: C, 53.85; H, 7.36; N, 7.54
Found: C, 53.74; H, 6.72; N, 7.47.
Example 10 l-(4-Fluorophenyl>-_-(3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocyclo- prop[f lisoindol-2-(lH)-yl)-l-butanone, hydrochloride, sesquihydrate
To a stirred solution of 3,3a,4,4a,5,5a,6,6a-octahydro-4,6-etheno- cycloproptf lisoindol (1.75 g, 0.011 mol), sodium carbonate (3.5 g, 0.035 mol) and triethylamine 3 mL in 50 mL of dimethylformamide is added 4-chloro-4'- fluorobutyrophenone (3.9 g, 0.019 mol). The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 200 mL methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the hydrochloride salt; m.p. 190- 191°C (1.3 g, 23% yield). Analysis for: C21H2 FNO • HC1 • 1 1/2 H2O Calculated: C, 64.86; H, 7.20; N, 3.60 Found: C, 65.31; H, 6.86; N, 3.73. Example 11
4-(l ,3,3a,4, 4a,5,6,6a,7,7a-Decahydro-4,7-etheno-lH-cyclobut[f 3- isoindol-2-yl)-l-(4---Uorophenyl)-l-butanone, hydrochloride
To a stirred solution of 2,3,3a,4,4a,5,6,6a,7,7a-decahydro-4,7- etheno-2H-cyclobut[f lisoindole (2.59 g, 0.014 mol), sodium carbonate (3.5 g,
0.035 mol) and triethylamine 3 mL in 50 mL of dimethylformamide is added 4- chloro-4,-fluorobutyrophenone (3.94 g, 0.019 mol). The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted in 3 x 100 mL methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the hydrochloride salt; m.p. 209- 210°C (1.8 g, 24% yield). Analysis for: C22H26FNO • HC1
Calculated: C, 70.50; H, 7.19; N, 3.72 Found: C, 69.61; H, 7.49; N, 4.0.
Example 12 3-[2-(2-Quinolinyl)ethyl 3-3-azabieyelo[3.2.2 Inonane, dihydrochloride, dihydrate
A mixture of 3-azabicyclo[3.2.2 Inonane (4 g, 0.032 mol), 2-vinyl- quinoline (7.7 g, 0.05 mol) and 2 mL of glacial acetic acid is refluxed for 48 hours in 150 mL of methanol. The solvent is removed under vacuum and the residue is dissolved in methylene chloride. The methylene chloride extract is washed with a saturated solution of sodium carbonate and water respectively, dried over anhydrous sodium sulfate and evaporated under reduced pressure. The title compound is separated by preparative HPLC using methanol as the eluent and is converted to the dihydrochloride salt; m.p. 195-197°C (5 g, 45% yield). Analysis for: C19H24N2 • 2 HC1 • 2 H2O Calculated: C, 58.61; H, 7.71; N, 7.19 Found: C, 59.01; H, 7.30; N, 7.27. Example 13
3-[3-[4-(2-Metho_-yphenyl)-l-piperazinyl Ipropyl 3-3-aza- bicyclo[3.2.2 Inonane, trihydrochloride, 3/4 hydrate
To a stirred solution of 3-azabicyclo[3.2.2 Inonane (1.1 g, 0.0088 mol), sodium carbonate (1 g, 0.0094 mol), and triethylamine 4 mL in
50 mL of dimethylformamide is added 4-(2-methoxyphenyl)-l-piperazinyl-
• propylchloride dihydrochloride (3.0 g, 0.0088 mol). The reaction mixture is stirred at room temperature overnight, the solvent is removed under vacuum and the remaining solid is extracted with 3 x 100 mL of methylene chloride. The methylene chloride extracts are collected, dried over anhydrous sodium sulfate and evaporated under reduced pressure.
The title compound is separated by preparative HPLC. It is converted to the hydrochloride salt; m.p. 252-254°C (0.9 g 24.3 ό yield). Analysis for: C22H35N3O • 3 HC1 • 3/4 H2O Calculated: C, 55.0; H, 8.22; N, 8.75 Found: C, 54.94; H, 7.71; N, 8.3.
Example 14
The ex vivo inhibition of 5-HTι^ serotonin receptor binding assay is used to determine whether the test compounds can cross the blood-brain barrier and affect the receptor in question and to give an indication of buspirone-like activity.
The assay is carried out as follows:
Several groups of rats (4 - 6 rats/group) are injected with test compound or the appropriate vehicle. Thirty minutes later, unless otherwise noted, rats are decapitated and their brains removed. Various brain regions are dissected and rapidly frozen and maintained at -70° C until used.
Hippocampal tissue is dissected and homogenized on ice in 40 vols of buffer (50 mM Tris HC1, pH = 7.7) using a Polytron homogenizer at setting 5 for 3 15 sec bursts. The homogenate is then centrifuged at 20,000 rpm (RC5-B; 40,000 g) and the supernatant discarded. The pellet is resuspended in 40 vols of the same buffer and incubated at 37° C for 10 minutes to aid in the removal of endogenous serotonin. The homogenate is then centrifuged (as above) and the supernatant discarded. The pellet is then resuspended in 100 vols of buffer B (50 mM Tris HC1, pH = 7.7 containing 0.1% ascorbate, 10 μM pargyline and 4 mM CaCl2) and sonicated. An aliquot is taken for protein determination by the Lowry method and the remainder stored frozen at -70° C until used.
The homogenate (50 μl; 0.4-0.6 mg protein/sample) is incubated with 100 μl (1.5-1.8 nM) 3H-8-hydroxy-2-(di-n-propylamino)tetraline in a final volume of 2 ml of buffer for 10 minutes at 37° C. At the end of the incubation, 3 ml of cold buffer A are added to each tube, and the contents rapidly filtered through Whatman GF/B glass filters. The filters are then rapidly washed 2 times with 3 ml of the same buffer, placed in scintillation vials, and shaken for 15 minutes with 10 ml of Hydrofluor (National Diagnostics) scintillation cocktail. The vials are then counted in a Packard 460 CD scintillation counter.
Specific binding is calculated for each of the treatment protocols and is defined as total binding less binding in the presence of excess unlabeled serotonin (1 μM). Specific binding obtained in vehicle-treated rats is compared to that obtained in animals receiving a single or various doses of test compound and expressed as percent of control. These results are then plotted as logit % binding vs. log concentration of test drug. Linear regression analysis then yields a straight line with 95% confidence limits from which an IC5Q can be inversely predicted. K[ (inhibition constant) for the test drug is then calculated by the formula:
IC i = 50 where Kj = 1.8 nm for 8-OH
. [ -8-OH DPAT 1 DPAT binding in hippocampus KD
The use of several doses of test compound also permits the calculation of an ID50 value, i.e. an inhibitory dose that displaces 50% of the specific binding ex vivo. Under these conditions, buspirone (30 mg/kg) displaced 46% of specific 3H-8-OH-DPAT binding from hippocampal membranes. When tested in this assay, the compounds of the invention gave the following results.
Table 1
Figure imgf000019_0001
The results show that compounds of the invention have a moderate to extremely strong affinity for binding to the 5-HTIA receptor site, evidencing a high potential for buspirone-like activity.
Example 15
The compounds of the invention are also studied for their ability to inhibit limbic D-2 dopamine receptor binding. This in vitro assay measures the ability of the compounds tested to bind to the dopamine receptor sites. Those compounds which exhibit a weak binding effect have a low liability to display potential extrapyramidal side effects.
The test is carried out as follows:
Several rats are decapitated and the brains are rapidly removed. Limbic brain tissue (nucleus accumbens, septal area, olfactory tubercle) is dissected and homogenized on ice in 9 volumes of buffer (50 mM Tris-HCl, 120 mM NaCl, 5 mM C1, 1 mM CaCl2, 1 mM MgCl2, 0.1% L-ascorbic acid, 10 μM pargyline HC1, pH 7.1) using a Polytron homogenizer at setting 5 for three 15-sec bursts. The homogenate is then diluted 4-fold with buffer and centrifuged at 30,000 x g for 20 minutes, and the supernatant is discarded. The pellet is resuspended in the same volume of buffer and recentrifuged as before, again discarding the supernatant. This pellet is then resuspended in the same volume of buffer used in the homogenization, and the protein content of this preparation is assayed by the Lowry method. The homogenate is stored frozen at -70° C until use.
Thirty μL of the homogenate (0.2-0.3 mg protein/sample) are incubated with 0.3 nM ^H-spiroperidol (New England Nuclear) and various concentrations of test drug in a final volume of 1 ml of the above buffer for 10 minutes in a 37° C water bath. At the end of the incubation, 3 ml of cold 50 mM Tris-Hcl, pH 7.7, are added to each tube, and the contents are rapidly vacuum-filtered through Whatman GF/B glass-fiber filters. The filters are then rapidly washed 3 times with 3 ml of the same buffer, placed in scintillation vials, and shaken for 15 minutes with 10 ml of Hydrofluor (National Diagnostics) scintillation cocktail. The vials are then counted in a Packard 460 CD scintillation counter.
Specific binding is defined as total binding less binding in the presence of 1 μM (+)butaclamol. Binding in the presence of various concentra- tions of test drug is expressed as a percent of specific binding when no drug is present. These results are then plotted as logit % binding vs. log concentra¬ tion of test drug. "Linear regression analysis then yields a straight line with 95% confidence limits from which an IC50 can be inversely predicted. Kj (inhibition constant) for the test drug is then calculated by the formula:
Figure imgf000020_0001
The results of testing of some of the compounds of the invention in this assay are presented in Table 2. Table 2
Figure imgf000021_0001
The results show that compounds of the invention display a range of inhibitory effects, with some compounds exhibiting a very weak inhibitory effect, evidencing a low potential for extrapyramidal side effects.

Claims

WHAT IS CLAIMED IS:
1. A compound having the formula
Figure imgf000022_0001
wherein R represents
Figure imgf000022_0002
where X is lower alkylene, vinylene or O; Y is lower alkylene or vinylene; n is 2 - 4; the dotted line represents an optional double bond; m is 1 - 3;
A is phenyl, benzoyl, pyridinyl, quinolinyl or quinoxalinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo, cyano, nitro or trifluoromethyl; or when m is >1, A represents the grouping
-B
Figure imgf000022_0003
where B is phenyl, pyrimidinyl, pyridinyl or pyrazinyl, or any of the foregoing substituted with lower alkyl, lower alkoxy, halo, cyano, nitro or trifluoromethyl, with the proviso that where R is
Figure imgf000023_0001
A is other than unsubstituted or substituted benzoyl or pyridinyl; and the pharmacologically acceptable salts thereof.
2. The compound of Claim 1, having the name 2,3,3a,4,4a,6a,7,7a- oetahydro-2-[3-(3-pyridinyl)propyl ]-4,7-etheno-lH-cyclobut[f 1 isoindole .
3. The compound of Claim 1, having the name l-(4-fluorophenyl)- 4-(l ,3,3a,4,4a,6a,7,7a-octahydro-4,7-etheno-2H-cyclobut[f ] isoindol-2-ylM- butanone.
4. The compound of Claim 1, having the name l-(4-fluorophenyl)-
4-(3,3a,4,5,6,7,8,8a-octahydro-4,8-ethenocyclohepta[c lpyrrol-2(lII)-yl>-l- butanone.
5. The compound of Claim 1, having the name 2,3,3a,4,4a,5,6,6a,7,7a-decahydro-2-[2-(2-quinolinyl)ethyl l-4,7-etheno-2H- cyclobut[f lisoindole.
6. The compound of Claim 1, having the name 2,3,3a,4,4a,6a,7,7a- octahydro-2-[2-(2-pyridinyl)ethyl l-4,7-etheno-lH-cyclobut[f 1 isoindole.
7. The compound of Claim 1, having the name 2,3,3a,4,4a,5,6,6a,7,7a-decahydro-2-[2-(2-pyridinyl)ethyl ]-4,7-etheno-lH- cyclobutEf lisoindole.
8. The compound of Claim 1, having the name 2,3,3a,4,4a,6a,6,7,7a-octahydro-2-[2-(2-quinolinyl)ethyl l-4,7-etheno-lH-cyclo- buttf lisoindole.
9. The compound of Claim 1, having the name 3-[3-[4-(3-chloro- phenyl)- 1-piperazinyl 1 propyl l-3-azabicyclo[3.2.2 Inonane.
10. The compound of Claim 1, having the name 2-[3-[4-(3-chloro- phenyl)- 1-piperazinyl 1 propyl l-2,3,3a,4,4a,5,6,7,7a-decahydro-4,7-etheno-lH- cyclobut[f lisoindole.
11* The compound of Claim 1, having the name l-(4-fluorophenyl)- 4-(3,3a,4,4a,5,5a,6,6a-octahydro-4,6-ethenocycloprop[f lisoindol-2-(lH)-yl)-l- butanone.
12. The compound of Claim 1, having the name 4- (1 ,3,3a,4,4a,5,6,6a,7,7a-decahydro-4,7-etheno-lH-cyclobut[f 1 isoindol-2-ylH-
(4-fluorophenyl)-l-butanone .
13. The compound of Claim 1, having the name 3-[2-(2-quinolinyl)- ethyl l-3-azabicyclo[3.2.2 Inonane.
14. The compound of Claim 1, having the name 3-[3-[4-(2-methoxy- phenyl>-l-piperazinyl 1 propyl l-3-azabicyclo[3.2.2 Inonane.
PCT/US1988/003924 1987-11-12 1988-11-10 Polycyclicamines with psychotropic activity WO1989004311A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11952087A 1987-11-12 1987-11-12
US119,530 1987-11-12

Publications (1)

Publication Number Publication Date
WO1989004311A1 true WO1989004311A1 (en) 1989-05-18

Family

ID=22384843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/003924 WO1989004311A1 (en) 1987-11-12 1988-11-10 Polycyclicamines with psychotropic activity

Country Status (3)

Country Link
EP (1) EP0348460A4 (en)
AU (1) AU2717288A (en)
WO (1) WO1989004311A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
WO2000030639A1 (en) * 1998-11-24 2000-06-02 Basf Aktiengesellschaft Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3323330A (en) * 1963-08-29 1967-06-06 Monk Sutton In Ashfield Ltd Sa Flat bed rib knitting machines
US4361565A (en) * 1981-12-28 1982-11-30 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4452799A (en) * 1981-12-23 1984-06-05 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
DE3321969A1 (en) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME
US4524206A (en) * 1983-09-12 1985-06-18 Mead Johnson & Company 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
US4562255A (en) * 1984-03-30 1985-12-31 American Home Products Corporation Substituted bi-alicyclic imides
US4567180A (en) * 1982-11-25 1986-01-28 Eisai Co., Ltd. Carboximide derivative and medicines containing same
US4598078A (en) * 1982-10-21 1986-07-01 Sumitomo Chemical Company, Limited N-(substituted piperazinyl) alkylbicyclic succinimide derivatives
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4757073A (en) * 1986-09-30 1988-07-12 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328390A (en) * 1962-02-27 1967-06-27 Tri Kem Corp Certain azabicycloalkane compounds

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) * 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
US3323330A (en) * 1963-08-29 1967-06-06 Monk Sutton In Ashfield Ltd Sa Flat bed rib knitting machines
US4411901A (en) * 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4452799A (en) * 1981-12-23 1984-06-05 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4361565A (en) * 1981-12-28 1982-11-30 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
US4598078A (en) * 1982-10-21 1986-07-01 Sumitomo Chemical Company, Limited N-(substituted piperazinyl) alkylbicyclic succinimide derivatives
US4567180A (en) * 1982-11-25 1986-01-28 Eisai Co., Ltd. Carboximide derivative and medicines containing same
DE3321969A1 (en) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME
US4524206A (en) * 1983-09-12 1985-06-18 Mead Johnson & Company 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
US4562255A (en) * 1984-03-30 1985-12-31 American Home Products Corporation Substituted bi-alicyclic imides
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4757073A (en) * 1986-09-30 1988-07-12 Bristol-Myers Company Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
J. Med. Chem., 26(2), 194-203, 1983. (USA) YEVICH, J.P. et al., "Buspirone Analogs. 1, Structure-Activity Relationships in A Series of N-Aryl- and Heteroarylpiperazine Derivatives). see entire document. *
J. Med.Chem., 29(8), 1476-82, 1986. (USA) NEW, JAMES S. et al., "Buspirone Analogs. 2. Structure-Activity Relationships of Aromatic Imide Derivatives". see entire document. *
J. Med.Chem., 31(7), 1382-92, 1988. (USA) ABOU-GHARBIA, MAGID, et al., "Polycyclic Aryl- and Hertoarylpiperazinyl Imides as 5-HTIA Receptor Ligands and Potential Anxiolytic Agents: Synthesis and Structure-Activity Relationship Studies". see entire document. *
Jpn. J. Pharmocol., 45(4), 493-500, 1987. (Japan) SHIMIZU, HIROSHI, et al, "Pharmocological Properties of SM-3997: A New Anxioselective Anxiolytic Candidate". see entire document. *
Jpn. J. Pharmocol., 46(3), 311-14, 1988. (Japan) SHIMIZU, HIROSHI, et al, "Interaction of SM-3997 with Serotonin Receptors in Rat Brain. see entire document. *
Life Science, 42(24), 2419-27, 1988. (USA) SHIMIZU, HIROSHI, et al., "Characterization of the Putative Anxiolytic SM-3997 Recognition Sites in *
See also references of EP0348460A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
WO2000030639A1 (en) * 1998-11-24 2000-06-02 Basf Aktiengesellschaft Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system

Also Published As

Publication number Publication date
AU2717288A (en) 1989-06-01
EP0348460A1 (en) 1990-01-03
EP0348460A4 (en) 1991-11-27

Similar Documents

Publication Publication Date Title
AU635851B2 (en) New piperidine, tetrahydropyridine and pyrrolidine derivatives, process for preparing these and pharmaceutical compositions containing them
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
SK10302001A3 (en) Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
JP2002504103A (en) 3-substituted 3,4-dihydrothieno [2,3-d] pyrimidine derivatives
EP0162695B1 (en) 6-oxygenated-1,3,,4,5-tetrahydrobenz(cd)indol-4-amines
EP0683166A1 (en) 3-Indolylpiperidines
EP0220051B1 (en) Isothiazolone derivatives
US4855430A (en) Polycyclicamine with psychotropic activity
EP0222474B1 (en) Gamma-carbolines
US4927934A (en) Polycyclicamine with psychotropic activity
EP0007399A1 (en) Indolylalkyl amines, pharmaceutical preparations containing them and process for their manufacture
WO1989004311A1 (en) Polycyclicamines with psychotropic activity
US6066637A (en) Indolyl derivatives as serotonergic agents
US6310208B1 (en) Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines
JPH08253479A (en) 1,2,5-thiadiazole derivative of antimigrainous indolylalkylpyridinyl- or -pirimidinylpiperazine
US4937347A (en) Polycyclicamine with psychotropic activity
KR20010031297A (en) 2-Substituted 1,2-Benzisothiazole Derivatives and Their Use as Serotonin Antagonists (5-HT1A, 5-HT1B and 5-HT1D)
EP0220873B1 (en) Fused bicyclic imides with psychotropic activity
US7332506B2 (en) Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression
EP1073651B1 (en) Indolyl derivatives as serotonergic agents
FI76786C (en) FOR EXAMINATION OF THERAPEUTIC ANALYSIS 4- (3-TRIFLUORMETHYLPHENYL) -1,2,3,6-TETRAHYDROPYRIDINER.
CZ20024192A3 (en) Indole derivatives
US4859671A (en) 2-substituted 1,2-benzisothiazol-3(2H)-one 1,1-dioxide useful as an anxiolytic agent
US5242933A (en) Piperidine, tetrahydropyridine and pyrrolidine compounds
JPH05247052A (en) 4-(4-piperidinyl)-thieno-(3,2-c)pyridine derivative of n-alkyl-gultalimide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1988910347

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988910347

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1988910347

Country of ref document: EP